Blood Glucose
Also known as: Blood sugar
Methodology & AI Transparency ⓘ
Blood Glucose Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is blood glucose? Blood glucose, or blood sugar, is the main sugar found in your blood.
- 2 Real-world patient consensus: Mapped to Type 1 & Type 2 Diabetes under ICD-10-CM E08.8 for Blood Glucose clinical workups.
- 3 Typical cash cost range: Clinicians assessing Blood Glucose focus on unrestrained hepatic gluconeogenesis [Blood Glucose E08.8] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Blood Glucose: Fasting Insulin [Blood Glucose E08.8] (3.0 – 7.0 uIU/mL (E08.8)) and CGM Time-in-Range (70–140 in Blood Glucose (E08.8: mg/dL)).
Ask our AI Specialists anything about Blood Glucose
What Is Blood Glucose?
What is blood glucose? Blood glucose, or blood sugar, is the main sugar found in your blood. It is your body's primary source of energy. It comes from the food you eat. Your body breaks down most of that food into glucose and releases it into your bloodstream. When your blood glucose goes up, it signals your pancreas to release insulin. Insulin is a hormone that helps the glucose get into your cells to be used for energy. What is diabetes? Diabetes is a disease in which your blood glucose levels are too high. When you have diabetes, your body doesn't make enough insulin, can't use it as well as it should, or both.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Blood Glucose (ICD-10 E08.8) is driven by unrestrained hepatic gluconeogenesis [Blood Glucose E08.8]; Cross-referenced with NIH MeSH (Blood Glucose), specialists in Type 1 & Type 2 Diabetes monitor CGM Time-in-Range (70–140 in Blood Glucose (E08.8: mg/dL)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Before a meal: 80 to 130 mg/dL
- • Two hours after the start of a meal: Less than 180 mg/dL
- • Presentation of Blood Glucose (E08.8): blurred vision fluctuations in Blood Glucose (E08.8: or slower healing)
- • Secondary Blood Glucose clinical sign: elevated fasting blood in Blood Glucose (E08.8: glucose or post-meal)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Blood Glucose Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E08.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Insulin [Blood Glucose E08.8] | 3.0 – 7.0 uIU/mL (E08.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Blood Glucose (E08.8: mg/dL)) | > 85% (E08.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Blood Glucose E08.8] | 4.8% – 5.6% (< 6.5% clinical target) (E08.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Blood Glucose
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Invokana (Canagliflozin) Invokana • RxCUI 1373463 | Sodium-Glucose Cotransporter 2 Inhibitor | 88% | $19.1169 | $ 640.00 /mo |
| Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Glucose and Sodium Chloride • RxCUI RXN-B03389799 | Osmotic Laxative | 87% | $3.2000 | $ 238.90 /mo |
| Inpefa (Sotagliflozin) Inpefa • RxCUI 2638689 | Sodium-Glucose Cotransporter 2 Inhibitor | 91% | $20.3408 | $ 640.00 /mo |
| Dapagliflozin and Saxagliptin Dapagliflozin and Saxagliptin Generic • RxCUI RXN-72205438-2440 | Sodium-Glucose Cotransporter 2 Inhibitor | 75% | $11.4327 | $ 185.00 /mo |
| Empagliflozin, Metformin Hydrochloride Synjardy XR, Synjardy • RxCUI 1862685 | Sodium-Glucose Cotransporter 2 Inhibitor | 82% | $11.2090 | $ 185.00 /mo |
| Jardiance (Empagliflozin) Jardiance • RxCUI 1545658 | Sodium-Glucose Cotransporter 2 Inhibitor | 80% | $1.8400 | $ 140.98 /mo |
| Mounjaro (Tirzepatide) Mounjaro • RxCUI 2601767 | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist | 92% | $523.0483 | $ 640.00 /mo |
| Farxiga (Dapagliflozin) Farxiga • RxCUI 1488574-B705184614 | Sodium-Glucose Cotransporter 2 Inhibitor | 92% | $12.0765 | $ 7.07 /mo |
| Empagliflozin and Metformin Hydrochloride Synjardy • RxCUI RXN-05970159-2455 | Sodium-Glucose Cotransporter 2 Inhibitor | 84% | $5.6067 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Blood Glucose)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| New Insights on Benefits and safety of GLP-1 agonists in the treatment of: What a 25,572-Participant Study Found For individuals with normal weight, both semaglutide and liraglutide are generally more effective for treating T2DM. Scientific reports • 2025-07-06 • Meta-Analysis | N = 25,572 | 99/100 | PMID 40619508 ↗ |
| New Insights on Evaluation and comparison of real-world benefits and safety of tirzepatide,: What a 8,499-Participant Study Found Out of the seven medications examined in this study, tirzepatide demonstrates the most effective antidiabetic and weight-reducing effects. BMC endocrine disorders • 2024-12-24 • Meta-Analysis | N = 8,499 | 99/100 | PMID 39719583 ↗ |
Blood Glucose Patient Community & “People Like Me” Threads
Filter Blood Glucose community threads and patient logs by age, biological sex, dosage, and treatment duration.